Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
CSBR

CSBR - Champions Oncology Inc Stock Price, Fair Value and News

$7.58-0.11 (-1.43%)
Market Closed

35/100

CSBR

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

35/100

CSBR

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$5.44

Target 3M

$6.4

Target 6M

$6.06

CSBR Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

CSBR Price Action

Last 7 days

6.9%

Last 30 days

9.9%

Last 90 days

11.3%

Trailing 12 Months

-29.4%

CSBR RSI Chart

CSBR Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

CSBR Valuation

Market Cap

105.3M

Price/Earnings (Trailing)

42.75

Price/Sales (Trailing)

1.8

EV/EBITDA

25.04

Price/Free Cashflow

18.66

CSBR Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$5.44

Target 3M

$6.4

Target 6M

$6.06

CSBR Fundamentals

CSBR Revenue

Revenue (TTM)

58.4M

Rev. Growth (Yr)

11.46%

Rev. Growth (Qtr)

7.43%

CSBR Earnings

Earnings (TTM)

2.5M

Earnings Growth (Yr)

-63.19%

Earnings Growth (Qtr)

157.51%

CSBR Profitability

EBT Margin

4.03%

Return on Equity

59.04%

Return on Assets

8.16%

Free Cashflow Yield

5.36%

CSBR Investor Care

Shares Dilution (1Y)

0.49%

Diluted EPS (TTM)

0.18

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202558.6M56.9M56.9M58.4M
202449.2M50.2M51.7M53.6M
202353.7M53.9M52.7M50.0M
202246.8M49.1M51.6M54.1M
202139.2M41.0M42.7M44.4M
202031.1M32.1M34.9M37.4M
201924.3M27.1M27.6M28.5M
201819.0M20.2M21.4M22.9M
201714.5M15.4M16.8M17.5M
201611.6M11.2M12.0M13.5M
20158.1M8.9M9.8M10.9M
201410.9M11.6M10.4M9.9M
20137.9M8.3M9.2M10.2M
20127.3M7.2M7.6M7.3M
201106.9M6.9M7.7M
Get all data in R, Python etc through our Historical Stock Data APIs

About Champions Oncology Inc

CSBR
Champions Oncology, Inc., a technology-enabled research company, provides transformative technology solutions for drug discovery and development in the United States. The company, through its Tumorgraft Technology Platform, provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice. It also offers Translational Oncology Solutions that utilizes its technology platform to assist pharmaceutical and biotechnology companies with their drug development process. In addition, it offers Lumin Bioinformatics, a dynamic analytic and visualization software that empowers cancer biologists to harness the power of computational science in a convenient and sophisticated tool. The company markets its products through internet, word of mouth, and sales force to patients and physicians. Champions Oncology, Inc. was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011. The company was incorporated in 1985 and is headquartered in Hackensack, New Jersey.
 CEO
 WEBSITEchampionsoncology.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES230

Champions Oncology Inc Frequently Asked Questions

CSBR is the stock ticker symbol of Champions Oncology Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Champions Oncology Inc is 105.26 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check CSBR's fair value in chart for subscribers.

The fair value guage provides a quick view whether CSBR is over valued or under valued. Whether Champions Oncology Inc is cheap or expensive depends on the assumptions which impact Champions Oncology Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CSBR.

As of Wed Jan 28 2026, CSBR's PE ratio (Price to Earnings) is 42.75 and Price to Sales (PS) ratio is 1.8. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CSBR PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Champions Oncology Inc has provided 0.077 (multiply by 100 for percentage) rate of return.